Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01189 (beta-endorphin)
 21,003 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The two mouse melanoma cell lines B16-F1 and B16-G4F retain their melanogenic capacity when cultured in vitro. Melanotropic peptides such as alpha-melanocyte-stimulating hormone (alpha-MSH) induce formation and release of melanin pigment in B16-F1 cells. In contrast, B16-G4F cells do not respond to alpha-MSH. Using receptor-binding analysis and photoaffinity crosslinking we demonstrate that the lack of response of B16-G4F cells to alpha-MSH is due to the absence of functional MSH receptors from the cell surface. Northern blot analysis of receptor mRNA revealed that MSH receptor mRNA is not expressed in B16-G4F cells. These cells represent a new tool for the study of signal pathways related to the control of melanogenesis in melanoma cells.
 ...
PMID:B16-G4F mouse melanoma cells: an MSH receptor-deficient cell clone. 848 88

Agouti protein is known to antagonize cAMP formation, tyrosinase activation and melanogenesis in mouse B16-F1 melanoma cells induced by alpha-melanocyte-stimulating hormone (alpha-MSH). We now demonstrate that although agouti binds to the melanocortin receptor MC1-R with an almost identical affinity to that of alpha-MSH, it does not antagonize the inhibitory action of alpha-MSH on the growth of B16-F1 cells. Instead it has a similar antiproliferative action with a half-maximal effective concentration of 13 nM. In G4F cells lacking MC1-R, agouti is without effect. Agouti was also found to induce MC1-R down-regulation with identical kinetics and magnitude as alpha-MSH. Thus, the different effects of agouti on B16-F1 cells proceed via interaction with MC1-R but are not exclusively antagonistic.
 ...
PMID:Agouti protein inhibits growth of B16 melanoma cells in vitro by acting through melanocortin receptors. 857 26

Non-transfected COS-7 cells have been found to possess functional melanotropin receptors on their cell surface. These receptors, and the properties of the melanocyte stimulating hormone (MSH) peptides can be characterized by measuring melanotropin stimulation of cAMP accumulation in the cells. In these cells we studied the ultra-long lasting super agonist [Nle(4)-D-Phe(7)]-alpha-MSH (NDP-alpha-MSH), and compared it with the endogenous MSH peptides with respect to potency, maximal activity, duration of action, and rate of desensitization. Surprisingly, NDP-alpha-MSH did not act as a full agonist in COS-7 cells. In multiple experiments, it could stimulate cAMP accumulation to approximately 50% of the level of alpha-MSH, beta-MSH and adrenocorticotropic hormone (ACTH). The MSH receptor mediating this activity is unknown. The time course of cAMP accumulation, and the duration of receptor activation was also investigated. In contrast to other systems NDP-alpha-MSH did not induce prolonged activity, with respect to cAMP accumulation, in COS-7 cells. The MSH receptors present in COS-7 were found to desensitize rapidly subsequent to pretreatment by any of the MSH peptides. As expected for a partial agonist, the activity of NDP-alpha-MSH desensitized more rapidly than any of the full agonists. Surprisingly, desensitization induced by pretreatment with NDP-alpha-MSH also occurred more rapidly than desensitization induced by the other MSH analogs.
 ...
PMID:Desensitization of melanotropin receptors in COS-7 cells. 861 75

There is increasing evidence that pro-opiomelanocortin-derived peptides have a role in controlling human skin pigmentation. In vitro, human epidermal melanocytes respond to melanocyte-stimulating hormone (MSH) with increases in melanogenesis and cell dendricity. However, in the present study, not all melanocyte cultures exhibited these changes and 24% were totally unresponsive to MSH. This unresponsiveness was limited to melanocytes from white Europeans but was particularly prevalent in cultures from individuals with red hair. Cyclic AMP, the second messenger of the melanocyte-associated MSH (MC-1) receptor, induced melanocyte dendricity, even in those cultures which were morphologically unresponsive to MSH. The cyclic nucleotide also increased melanogenesis in the cultures that responded melanogenically to MSH but its effect was reduced in those cultures that were unresponsive to MSH. Thus, while the morphological data support the hypothesis that unresponsiveness is mediated at the MSH receptor, intracellular events may also be important in determining melanogenic unresponsiveness to MSH.
 ...
PMID:Unresponsiveness of human epidermal melanocytes to melanocyte-stimulating hormone and its association with red hair. 864 12

Stable expression of the MSH receptor in a homologous system is important for the study of the function and mechanism of signalling of this receptor. This is the first report on the stable expression of the human alpha-MSH receptor in the mouse melanoma G4F clone which lacks an endogenous MSH receptor. Several stable transfectant cell lines were obtained all of which express the human MSH receptor in high numbers. Human MSH receptor mRNA expression was detected by Northern blot analysis. Competition binding experiments showed that the MSH receptors expressed in these cells have the same affinity for [Nle4,D-Phe7]-alpha-MSH as the MSH receptors of the human HBL melanoma cell line. Several of the transfectant cell lines produced melanin constitutively, some of them secreting melanin into the medium whereas other clones did not secrete melanin. MSH and cholera toxin did not or only marginally increase melanogenesis in these clones, and forskolin had an opposite effect. These results suggest that the human MSH receptor may be constitutively active in these transfected mouse melanoma cells.
 ...
PMID:Stable expression of the human MSH receptor in a mouse melanoma cell line. 890 30

Melanoma cells express receptors for melanocyte-stimulating hormone (MSH) in variable abundance. CGP 41251, a derivative of staurosporine with an increased selectivity for protein kinase C (PKC) inhibition, was found to modulate MSH receptors in human D10 and HBL cells and in the mouse B16 cell line. Up-regulation was observed in D10 and B16 cells at a concentration of 290 nM and 190 nM, respectively. In HBL cells, however, the PKC inhibitor induced a pronounced MSH receptor down-regulation with an EC50 of only 32 nM. In D10 and HBL cells, alpha-MSH and CGP 41251 synergistically regulated MSH receptors whereas these agents had an antagonistic effect in B16 cells. PKC stimulation by short-term treatment with phorbol ester had an opposite effect on MSH receptors as compared to CGP 41251. In B16 cells, CGP 41251 at a concentration of 100 nM increased the sensitivity to MSH-induced melanogenesis. The staurosporine derivative inhibited proliferation of HBL, B16, and D10 cells at EC50s of 180 nM, 190 nM, and 520 nM, respectively. Furthermore, CGP 41251 increased the dendricity of the cells. In a concentration range between 300 nM and 1 mu M, CGP 41251 induced a sharp increase of the mean cell diameter from 16 mu m to 19 mu m. Thus, the effects of the selective PKC inhibitor on MSH receptors are induced at lower concentrations than needed for the inhibition of proliferation or for the change in cell morphology. These results suggest that the number of MSH receptors expressed on the surface of cultured melanoma cells correlates with the level of constitutive PKC activity in individual cell lines.
 ...
PMID:A selective protein kinase C inhibitor (CGP 41251) positively and negatively modulates melanoma cell MSH receptors. 890 45

The current study aims to ascertain the fate of the melanocyte stimulating hormone (MSH) receptor and its ligand [Nle4, D-Phe7] alpha-MSH (NDP-MSH) following binding to murine B16 melanoma cells. Cells were incubated with [125I]-NDP-MSH for up to 180 min and binding, internalization and degradation determined. Intracellular trafficking of the radiolabel was assessed using Percoll density gradient centrifugation of homogenized cells. Receptor down-regulation and receptor mRNA levels were also measured over 96 hr after exposure to 1 microM ligand. NDP-MSH accumulation increased with time in a temperature-dependent manner and was inhibited by excess peptide. The ligand was rapidly internalized and translocated to the lysosomal compartment where it was degraded. Internalization was accompanied by a loss or down-regulation of cell surface receptors, suggesting internalization of the NDP-MSH-receptor complex. No recycling of the receptors between the plasma membrane and intracellular compartments could be detected in this cell-line. Approximately 15% of the surface receptors were resistant to down-regulation, possibly indicating receptor heterogeneity. Down-regulation persisted for up to 96 hr and was accompanied by a decrease in MSH receptor mRNA levels 48 hr after treatment. However, before this time, transcript levels were the same in treated and control cells. In contrast to what was seen with NDP-MSH, cell surface receptors removed with trypsin were rapidly replaced. These results show that NDP-MSH not only induced MSH receptor internalization but also inhibited receptor turnover, resulting in a prolonged down-regulation. It is concluded that, in B16 cells, the MSH receptor undergoes ligand-dependent internalization, resulting in a prolonged down-regulation.
 ...
PMID:Binding and internalization of the melanocyte stimulating hormone receptor ligand [Nle4, D-Phe7] alpha-MSH in B16 melanoma cells. 902 81

Melanotropin is a peptide having several functions, including the stimulation of melanogenesis and the modulation of proliferation of melanocytes and melanoma cells. It acts through binding to high-affinity receptors of the melanocortin-1 subtype, exclusively expressed in cells of the melanocytic lineage. Elevated levels of immunoreactive alpha-melanotropin were previously reported in melanoma cell lines, tumours and plasma from patients with melanoma. Here, we show that this high ectopic production of melanotropin is restricted to melanoma and non-pituitary tumours with the same neuroectodermic origin. The occurrence of a melanotropin-specific autocrine loop was further investigated in human melanoma cells. Immunoreactive alpha-melanotropin was spontaneously released from a melanoma cell line (HBL) expressing melanotropin receptors on the cell surface. This release was significantly increased in the presence of melanotropin-related peptides such as corticotropin-(4-10)-peptide and beta-melanotropin, competing for binding to the melanotropin receptor and was directly correlated to the displacement potential of these peptides. Both spontaneous and induced releases of immunoreactive alpha-melanotropin could be blocked at low temperatures, suggesting the involvement of intracellular protein movement in the release mechanism. The release of immunoreactive alpha-melanotropin was not significant in melanoma cells expressing very low levels of melanotropin receptors (IGR3) or in non-melanoma cells (SCC1). However, upon expression of the melanocortin-1 receptor cDNA into IGR3 cells, spontaneous and competition-induced releases of immunoreactive alpha-melanotropin were both increased and also blocked at low temperatures. This observation further underlines a role for the melanotropin receptor in the release of immunoreactive alpha-melanotropin. These experiments indicate that an autocrine loop between the melanocortin-1 receptor and immunoreactive alpha-melanotropin may be functional in human melanoma cells.
 ...
PMID:Immunoreactive alpha-melanotropin as an autocrine effector in human melanoma cells. 910 67

We have found that a melanization inhibitory factor (MIF) extracted from the ventral skin of Rana forreri has a slight inhibitory effect on the activity levels of tyrosinase and dopachrome tautomerase in B16/F10 and Cloudman S-91 murine melanoma cell lines. Furthermore, this factor appears to block the effects of alpha-MSH on these enzymatic activities. However, MIF treatment does not affect the melanogenic action of theophylline on the same cells, suggesting that MIF acts proximal to MSH-mediated cAMP formation, possibly by interaction with the MSH receptor. In this way, we show that this amphibian factor has biological activity on mammalian melanocytes. This suggests the existence of mammalian counterparts of amphibian MIF in the mouse integument that might regulate epidermal melanocytes. These peptides might be related to the agouti protein, as they share similar mechanisms of action. The interaction of different peptides with the MSH receptor would be a complex but general mechanism responsible for many mammalian coat color variants.
 ...
PMID:The amphibian melanization inhibiting factor (MIF) blocks the alpha-MSH effect on mouse malignant melanocytes. 912 55

Ultraviolet B (UVB) radiation is known to induce reactive oxygen species (ROS) in the skin. The skin, however, counteracts ROS by both constitutional and newly produced antioxidants. One such antioxidant, adult T cell leukemia-derived factor (ADF), a human homologue of thioredoxin (TRX), was shown to be efficiently produced in and released from cultured normal human keratinocytes after UVB irradiation by Northern and Western blot analyses and enzyme-linked immunoabsorbent assay (ELISA). Recombinant ADF (rADF) did not rescue UVB-induced melanocyte death, either when added pre- or post-UV irradiation. However, further addition of neutralizing antibody caused cell death of both keratinocytes and melanocytes. rADF was shown to induce higher expression in melanocortin-1 receptor (MC1-R) mRNA accompanied by increased binding activity using 125I labeled [Nle4, D-Phe7]-alpha-MSH in melanocytes, leading to the enhanced increment of DNA synthesis. Taken together, it was shown that released ADF from UVB-irradiated keratinocytes acts as a survival factor for both keratinocytes and melanocytes but does not rescue UV-induced melanocyte death. Further, it may work as one of the stimulatory factors for UVB-induced melanogenesis by upregulating MSH-R binding activity in combination with the enhanced DNA synthesis by alpha-MSH.
 ...
PMID:The effect of ultraviolet B induced adult T cell leukemia-derived factor/thioredoxin (ADF/TRX) on survival and growth of human melanocytes. 917 Jan 66


<< Previous 1 2 3 4 5 6 7 Next >>